FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended SEPTEMBER 30, 2007
------------------
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
----- -----
Commission file number 0-10248
------------------------------
FONAR CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 11-2464137
------------------------------- -------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification
incorporation or organization) No.)
110 Marcus Drive Melville, New York 11747
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(631) 694-2929
---------------------------------------------------
Registrant's telephone number, including area code:
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES X NO
--- ---
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). YES NO X
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the close of the latest practicable date.
Class Outstanding at October 31, 2007
----------------------------------------- -------------------------------
Common Stock, par value $.0001 4,894,261
Class B Common Stock, par value $.0001 158
Class C Common Stock, par value $.0001 382,513
Class A Preferred Stock, par value $.0001 313,451
FONAR CORPORATION AND SUBSIDIARIESINDEXPART I - FINANCIAL INFORMATION
PAGE
Item 1. Financial Statements
Condensed Consolidated Balance Sheets - September 30, 2007
(Unaudited) and June 30, 2007
Condensed Consolidated Statements of Operations for
the Three Months Ended September 30, 2007 and
September 30, 2006 (Unaudited)
Condensed Consolidated Statements of Comprehensive
Loss for the Three Months Ended
September 30, 2007 and September 30, 2006 (Unaudited)
Condensed Consolidated Statements of Cash Flows for
the Three Months Ended September 30, 2007 and
September 30, 2006 (Unaudited)
Notes to Condensed Consolidated Financial Statements (Unaudited)
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About
Market Risk
Item 4. Controls and Procedures
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Item 2. Changes in Securities
Item 3. Defaults Upon Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
Signatures
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
ASSETS September 30, June 30,
2007 2007
(UNAUDITED)
Current Assets: ------------- --------
Cash and cash equivalents $ 1,495 $ 1,470
Marketable securities 2,693 1,979
Accounts receivable - net 4,047 3,528
Accounts receivable - related parties -net 556 445
Medical receivables - net 2,359 2,781
Management fee receivable - net 4,163 5,096
Management fee receivable - related
medical practices - net 2,111 1,354
Costs and estimated earnings in excess
of billings on uncompleted contracts 31 -
Inventories 4,776 4,466
Current portion of advances and notes to related
medical practices 260 216
Current portion of notes receivable less discount for
below market interest 589 578
Prepaid expenses and other current assets 1,358 1,103
-------- --------
Total Current Assets 24,438 23,016
-------- --------
Property and equipment - net 4,805 5,159
Advances and notes to related medical practices - net 398 474
Notes receivable less discount for below market interest 5,388 5,528
Other intangible assets - net 5,445 5,345
Other assets 1,705 1,688
-------- --------
Total Assets $ 42,179 $ 41,210
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
September 30, June 30,
LIABILITIES AND STOCKHOLDERS' EQUITY 2007 2007
(UNAUDITED)
Current Liabilities: ------------- --------
Current portion of long-term debt and
capital leases $ 256 $ 257
Accounts payable 3,315 3,940
Other current liabilities 7,400 7,755
Unearned revenue on service contracts 4,486 4,607
Unearned revenue on service
contracts - related parties 564 460
Customer advances 10,669 10,039
Customer advance - related party 492 42
Billings in excess of costs and estimated
earnings on uncompleted contracts 4,906 3,481
-------- --------
Total Current Liabilities 32,088 30,581
Long-Term Liabilities:
Due to related medical practices 93 93
Long-term debt and capital leases,
less current portion 901 956
Other liabilities 130 150
-------- --------
Total Long-Term Liabilities 1,124 1,199
-------- --------
Total Liabilities 33,212 31,780
-------- --------
Minority interest 143 532
-------- --------
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED, except share data)
September 30, June30,
LIABILITIES AND STOCKHOLDERS' EQUITY 2007 2007
(continued) (UNAUDITED)
------------- --------
STOCKHOLDERS' EQUITY:
Class A non-voting preferred stock $.0001 par value;
1,600,000 authorized, 313,451 issued and outstanding
at September 30, 2007 and June 30, 2007 - -
Common Stock $.0001 par value; 30,000,000 shares
authorized at September 30, 2007 and June 30, 2007,
4,905,850 issued at September 30, 2007 and 4,885,850
at June 30, 2007; 4,894,207 outstanding at
September 30, 2007 and 4,874,207 at June 30, 2007 1 1
Class B Common Stock $.0001 par value; 800,000 shares
authorized, (10 votes per share), 158 issued and
outstanding at September 30, 2007 and June 30, 2007 - -
Class C Common Stock $.0001 par value; 2,000,000 shares
authorized, (25 votes per share), 382,513 issued
and outstanding at September 30, 2007 and June 30, 2007 - -
Paid-in capital in excess of par value 172,206 172,072
Accumulated other comprehensive loss (105) (104)
Accumulated deficit (162,081) (161,872)
Notes receivable from employee stockholders (522) (524)
Treasury stock, at cost - 11,643 shares of common stock
at September 30, 2007 and June 30, 2007 (675) (675)
-------- --------
Total Stockholders' Equity 8,824 8,898
-------- --------
Total Liabilities and Stockholders' Equity $ 42,179 $ 41,210
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)(000's OMITTED, except per share data)
FOR THE THREE MONTHS
ENDED SEPTEMBER 30,
-------------------
2007 2006
REVENUES -------- --------
Product sales - net $ 2,589 $ 2,317
Product sales - related parties - net - 139
Service and repair fees - net 2,465 2,281
Service and repair fees - related parties - net 254 242
Management and other fees - net 1,885 -
Management and other fees - related medical
practices - net 1,476 2,804
-------- --------
Total Revenues - Net 8,669 7,783
-------- --------
COSTS AND EXPENSES
Costs related to product sales 2,811 2,442
Costs related to product sales - related parties - 144
Costs related to service and repair fees 1,190 1,243
Costs related to service and repair
fees - related parties 123 132
Costs related to management and other fees 1,089 -
Costs related to management and other
fees - related medical practices 947 2,004
Research and development 1,163 1,432
Selling, general and administrative, inclusive
of compensatory element of stock issuances of
$0 and $ 98 for the three months ended
September 30, 2007 and 2006, respectively 5,287 6,427
Provision for bad debts 165 50
-------- --------
Total Costs and Expenses 12,775 13,874
-------- --------
Loss From Operations (4,106) (6,091)
Interest Expense (102) (71)
Investment Income 180 199
Interest Income - Related Parties 9 11
Other Income 6 39
Minority Interest in Income of Partnerships (162) (192)
Gain on Sale of Investment 571 -
Gain on Sale of Consolidated Subsidiary 3,395 -
-------- --------
NET LOSS $ (209) $ (6,105)
======== ========
Basic and Diluted Loss Per Common Share $(.04) $(1.29)
======== ========
Other comprehensive (loss) income net of tax:
Unrealized (losses) gains on securities,
net of tax (2) 86
-------- --------
Total comprehensive loss $ (211) $(6,019)
======== ========
Weighted Average Number of Common Shares Outstanding 4,884,207 4,738,088
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(000'S OMITTED)
FOR THE THREE MONTHS
ENDED SEPTEMBER 30,
-------------------
2007 2006
-------- --------
Cash Flows from Operating Activities
Net loss $ (209) $ (6,105)
Adjustments to reconcile net loss to
net cash used in operating activities:
Minority interest in income of partnerships 162 192
Depreciation and amortization 558 656
Gain on sale of consolidated subsidiary (3,395) -
Gain on sale of investment (571) -
Provision for bad debts 165 50
Compensatory element of stock issuances - 98
Stock issued for costs and expenses 135 1,851
(Increase) decrease in operating assets, net:
Accounts, management fee and medical receivable(s) (1,363) 359
Notes receivable 130 71
Costs and estimated earnings in excess of
billings on uncompleted contracts (31) 2,902
Inventories (310) 839
Principal payments received on sales type lease - 47
Prepaid expenses and other current assets (255) (707)
Other assets (20) (30)
Advances and notes to related medical practices 19 5
Increase (decrease) in operating liabilities, net:
Accounts payable (625) (967)
Other current liabilities (373) (149)
Customer advances 1,080 1,332
Billings in excess of costs and estimated
earnings on uncompleted contracts 1,425 (1,015)
Other liabilities (20) (14)
Income taxes payable - (8)
-------- --------
Net cash used in operating activities (3,498) (593)
-------- --------
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(000'S OMITTED)
FOR THE THREE MONTHS
ENDED SEPTEMBER 30,
-------------------
2007 2006
-------- --------
Cash Flows from Investing Activities:
Sales of marketable securities 50 398
Purchases of marketable securities (765) -
Purchases of property and equipment (51) (117)
Costs of capitalized software development (187) (184)
Cost of patents (88) (165)
Proceeds from sale of investment 571 -
Proceeds from sale of consolidated subsidiary 4,142 -
-------- --------
Net cash provided by (used in) investing activities 3,672 (68)
-------- --------
Cash Flows from Financing Activities:
Distributions to holders of minority interest (95) (203)
Repayment of borrowings and capital
leases (56) (45)
Net proceeds from exercise of stock options
and warrants - 50
Net proceeds from sale of common stock - 373
Repayment of notes receivable from employee
stockholders 2 37
-------- --------
Net cash (used in) provided by financing activities (149) 212
-------- --------
Net Increase (Decrease) in Cash and Cash Equivalents 25 (449)
Cash and Cash Equivalents - Beginning of Period 1,470 4,557
-------- --------
Cash and Cash Equivalents - End of Period $ 1,495 $ 4,108
======== ========
See accompanying notes to condensed consolidated financial statements
(unaudited).
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION & LIQUIDITY & CAPITAL RESOURCES
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by accounting principles generally accepted in the United
States of America for complete financial statements. In the opinion of
management, all adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation have been included. Operating results for the
three months ended September 30, 2007 are not necessarily indicative of the
results that may be expected for the fiscal year ending June 30, 2008. For
further information, refer to the consolidated financial statements and
footnotes thereto included in the Company's Annual Report on Form 10-K filed on
October 2, 2007 for the fiscal year ended June 30, 2007.
Liquidity and Capital Resources
The Company's principal source of liquidity has been derived from revenues, as
well as cash provided by previous debt and equity financing. The Company's
management currently expects this to continue. At September 30, 2007, the
Company had a working capital deficit of approximately $7.7 million. For the
three months ended September 30, 2007, the Company incurred a net loss of
approximately $209,000 which included non-cash charges of approximately
$858,000.
In July 2007, the Company sold its 50% interest (to an unrelated third party) in
an entity that provided management services to a diagnostic center in Orlando,
Florida and 20% interest in an unconsolidated entity and received proceeds of
approximately $4.8 million.
Sales levels remain weak and the Company continues to focus its efforts on
increased advertising and marketing campaigns, and distribution programs to
strengthen the demand for Fonar's products. Management anticipates that Fonar's
capital resources will improve as Fonar's MRI scanner products gain wider market
recognition and acceptance resulting in increased product sales. If the Company
is not successful with its current marketing efforts to increase sales, then the
Company will experience a shortfall in cash necessary to sustain operations at
their current levels. Should weak demand continue, the Company has determined it
will be necessary to reduce overhead expenses or seek other sources of funds
through the issuance of equity or debt financing in order to maintain sufficient
funds available to operate subsequent to September 30, 2008. The reduction in
overhead expenses might need to be substantial in order for the Company to
streamline operations to an efficient level.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The condensed consolidated financial statements include the accounts of FONAR
Corporation, its majority and wholly-owned subsidiaries and partnerships
(collectively the "Company"). All significant intercompany accounts and
transactions have been eliminated in consolidation.
Reverse Stock Split
On April 17, 2007, the Company effected a one-for-twenty-five reverse split of
its issued and outstanding common stock, Treasury Shares of the Common Stock,
the Class B Common Stock, the Class C Common Stock, the Class A Non-Voting
Preferred Stock and Preferred Stock. At such time, the Company also reduced the
number of its authorized shares available for issuance for each class of stock.
The accompanying condensed consolidated financial statements, notes and other
references to share and per share data have been retroactively restated to
reflect the reverse stock splits for all periods presented.
Earnings (Loss) Per Share
Basic earnings (loss) per share ("EPS") is computed based on weighted average
shares outstanding and excludes any potential dilution. In accordance with EITF
03-6, "Participating Securities and the Two-Class method under FASB Statement
No. 128" ("EITF 03-6"), the Company's participating convertible securities,
which include Class B common stock and Class C common stock, are not included in
the
computation of basic EPS for three months ended September 30, 2007 and 2006,
because the participating securities do not have a contractual obligation to
share in the losses of the Company.
Diluted EPS reflects the potential dilution from the exercise or conversion of
all dilutive securities into common stock based on the average market price of
common shares outstanding during the period. The number of common shares
potentially issuable upon the exercise of certain options and warrants or
conversion of the participating convertible securities that were excluded from
the diluted EPS calculation was approximately 279,000 and 281,000 because they
were antidilutive as a result of a net loss for the three months ended September
30, 2007 and 2006, respectively.
Stock Options and Warrants and Similar Equity Instruments
In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share-Based
Payment" SFAS 123R. SFAS 123R requires the compensation cost relating to
stock-based payment transactions be recognized in financial statements. That
cost will be measured based on the fair value of the equity or liability
instruments issued on the grant date of such instruments, and will be recognized
over the period during which an individual is required to provide service in
exchange for the award (typically the vesting period). SFAS 123R covers a wide
range of stock-based compensation arrangements including stock options,
restricted stock plans, performance-based awards, stock appreciation rights, and
employee stock purchase plans. SFAS 123R replaces SFAS 123 and supersedes APB
Opinion 25.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Stock Options and Warrants and Similar Equity Instruments (Continued)
On July 1, 2005, the Company adopted SFAS 123R using the modified prospective
method, in which compensation cost is recognized beginning with the effective
date (a) based on the requirements of SFAS 123R for all share-based payments
granted after the effective date and (b) based on the fair value as measured
under SFAS 123 for all awards granted to employees prior to the effective date
of SFAS 123R that remain unvested on the effective date.
The adoption of SFAS 123R's fair value method did not have a significant impact
on our result of operations. SFAS 123R requires the benefits of tax deductions
in excess of recognized compensation cost to be reported as a financing cash
flow, rather than as an operating cash flow as required under current
literature. It is unlikely that the Company will have near term benefits from
tax deductions. This requirement will reduce net operating cash flows and
increase net financing cash flows in periods after adoption. The Company cannot
estimate what those amounts will be in the future because of various factors,
including but not limited to the timing of employee exercises and whether the
Company will be in a taxable position. At this time, there would be no tax
impact related to the prior periods since the Company has a net loss.
For the period ending prior to July 1, 2005, as permitted under SFAS No. 148,
"Accounting for Stock-Based Compensation Transactions and Disclosure", which
amended SFAS No. 123, "Accounting for Stock-Based Compensation", the Company had
elected to continue to follow the intrinsic value method in accounting for its
stock-based employee compensation arrangements as defined by Accounting
Principles Board Opinion ("APB") No. 25 "Accounting for Stock Issued to
Employees", and related interpretations including FASB Interpretation No. 44,
"Accounting for Certain Transactions Involving Stock Compensation", an
interpretation of APB No. 25. No stock-based employee compensation cost was
reflected in operations, as all options granted under those plans had an
exercise price equal to the market value of the underlying common stock on the
date of grant.
Recent Accounting Pronouncements
In February 2006, the FASB issued SFAS NO. 155, Accounting for Certain Hybrid
Financial Instruments--An Amendment of FASB No. 133 and 140. The purpose of SFAS
statement No. 155 is to simplify the accounting for certain hybrid financial
instruments by permitting fair value re-measurement for any hybrid financial
instrument that contains an embedded derivative that otherwise would require
bifurcation. SFAS No. 155 also eliminates the restriction on passive derivative
instruments that a qualifying special-purpose entity may hold. SFAS No. 155 is
effective for all financial instruments acquired or issued after the beginning
of any entity's first fiscal year beginning after September 15, 2006. The
adoption of this standard on July 1, 2007 did not have a material effect on the
Company's consolidated financial statements.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements (Continued)
In March 2006, the FASB issued SFAS No. 156, Accounting for Servicing of
Financial Assets, an Amendment of SFAS No. 140. SFAS No. 156 requires separate
recognition of a servicing asset and a servicing liability each time an entity
undertakes an obligation to service a financial asset by entering into a
servicing contract. This statement also requires that servicing assets and
liabilities be initially recorded at fair value and subsequently adjusted to the
fair value at the end of each reporting period. This statement is effective in
fiscal years beginning after September 15, 2006. The adoption of this standard
on July 1, 2007 did not have a material effect on the Company's consolidated
financial statements.
In September, 2006, the FASB issued SFAS No. 157, "Fair Value Measurements",
which defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements. This standard applies under
other accounting pronouncements that require or permit fair value measurements,
but does not require any new fair value measurements. SFAS No. 157 will become
effective for the Company in fiscal 2009. We are currently assessing the impact
of SFAS No. 157; however, we do not believe the adoption of this standard will
have a material effect on the Company's condensed consolidated financial
statements.
In February, 2007, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities (FAS 159). FAS 159 provides Companies
with an option to report selected financial assets and liabilities at fair
value. FAS 159's objective is to reduce both complexity in accounting for
financial instruments and the volatility in earnings caused by measuring related
assets and liabilities differently. FAS 159 also establishes presentation and
disclosure requirements designed to facilitate comparisons between Companies
that choose different measurement attributes for similar types of assets and
liabilities. FAS 159 requires Companies to provide additional information that
will help investors and other users of financial statements to more easily
understand the effect of the Company's choice to use fair value on its earnings.
It also requires entities to display the fair value of those assets and
liabilities for which the Company has chosen to use fair value on the face of
the balance sheet. FAS 159 is effective as of the beginning of an entity's first
fiscal year beginning after November 15, 2007. Early adoption is permitted as of
the beginning of the previous fiscal year provided that the entity makes that
choice in the first 120 days of that fiscal year and also elects to apply the
provisions of Statement 157. The Company did not early adopt FAS 159. The
Company is currently assessing the impact of SFAS No. 159; however we do not
believe the adoption of this standard will have a material effect on its
consolidated financial statements.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements (Continued)
In March 2007, the Financial Accounting Standards Board (FASB) ratified the
Emerging Issues Task Force (EITF) consensus on EITF Issue No. 06-10, "Accounting
for Collateral Assignment Split Dollar Life Insurance." This EITF indicates that
an employer should recognize a liability for postretirement benefits related to
collateral assignment split-dollar life insurance arrangements. In addition, the
EITF provides guidance for the recognition of an asset related to a collateral
assignment split-dollar life insurance arrangement. The EITF is effective for
fiscal years beginning after December 15, 2007. The Company will adopt the EITF
as required and management does not expect it to have any impact on the
Company's results of operations, financial condition and liquidity.
In June 2006, the EITF reached a consensus on Issue No. 06-3 ("EITF 06-3"), "
Disclosure Requirements for Taxes Assessed by a Governmental Authority on
Revenue-Producing Transactions ." The consensus allows companies to choose
between two acceptable alternatives based on their accounting policies for
transactions in which the company collects taxes on behalf of a governmental
authority, such as sales taxes. Under the gross method, taxes collected are
accounted for as a component of sales revenue with an offsetting expense.
Conversely, the net method allows a reduction to sales revenue. If such taxes
are reported gross and are significant, companies should disclose the amount of
those taxes. The guidance should be applied to financial reports through
retrospective application for all periods presented, if amounts are significant,
for interim and annual reporting beginning after December 15, 2006 with early
adoption is permitted. The adoption of this standard did not have a material
effect on the Company's condensed consolidated financial statements.
Effective January 1, 2007, the Company adopted the provisions of FASB
Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an
interpretation of FASB Statement No. 109" ("FIN 48). FIN 48 prescribes a
recognition threshold and a measurement attribute for the financial statement
recognition and measurement attribute for the financial statement recognition
and measurement of tax positions taken or expected to be taken in a corporate
tax return. For those benefits to be recognized, a tax position must be
more-likely-than-not to be sustained upon examination by taxing authorities.
Differences between tax positions taken or expected to be taken in a tax return
and the benefit recognized and measured pursuant to the interpretation are
referred to as "unrecognized benefits". A liability is recognized (or amount of
net operating loss carry forward or amount of tax refundable is reduced) for an
unrecognized tax benefit because it represents an enterprise's potential future
obligation to the taxing authority for a tax position that was not recognized as
a result of applying the provisions of FIN 48.
In accordance with FIN 48, interest costs related to unrecognized tax benefits
are required to be calculated (if applicable) and would be classified as
"Interest expense, net". Penalties if incurred would be recognized as a
component of "General and administrative" expenses.
The Company files corporate income tax returns in the United States (federal)
and in various state and local jurisdictions. In most instances, the Company is
no longer subject to federal, state and local income tax examinations by tax
authorities for years prior to 2003.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements (Continued)
The adoption of the provisions of FIN 48 did not have a material impact on the
Company's condensed consolidated financial position and results of operations.
As of September 30, 2007, no liability for unrecognized tax benefits was
required to be recorded.
The Company recognized a deferred tax asset of approximately $72 million as of
September 30, 2007, primarily relating to net operating loss carryforwards of
approximately $156 million, available to offset future taxable income through
2028.
The ultimate realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those temporary differences
become deductible. The Company considers projected future taxable income and tax
planning strategies in making this assessment. At present, the Company does not
have a sufficient history of income to conclude that it is more-likely-than-not
that the Company will be able to realize all of its tax benefits in the near
future and therefore a valuation allowance was established for the full value of
the deferred tax asset. A valuation allowance will be maintained until
sufficient positive evidence exists to support the reversal of any portion or
all of the valuation. Should the Company become profitable in future periods
with supportable trends, the valuation allowance will be reversed accordingly.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year
presentation. The reclassifcations did not have any effect on reported
consolidated net losses for any periods presented.
NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
Medical Receivables
The Company was assigned medical receivables valued at $11,775,000, in
connection with the satisfaction of the management fees and termination fees
related to a Termination and Replacement Agreement dated May 23, 2005. The
balance of the net medical receivables as of September 30, 2007 was $2,359,000.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
(Continued)
Accounts Receivable and Management Fee Receivable
Receivables, net is comprised of the following at September 30, 2007:
(000's Omitted)
Gross Allowance for
Receivable doubtful accounts Net
---------- ----------------- -------------
Receivables from equipment
sales and service contracts $ 5,296 $ 1,249 $ 4,047
========== ================= =============
Receivables from equipment
sales and service contracts-
related parties $ 1,202 $ 646 $ 556
========== ================= =============
Management fee receivables $ 6,373 $ 2,210 $ 4,163
========== ================= =============
Management fee receivables
from related medical
practices ("PC's") $ 4,204 $ 2,093 $ 2,111
========== ================= =============
The Company's customers are concentrated in the healthcare industry.
The Company's receivables from the related and non-related professional
corporations (PC's) substantially consists of fees outstanding under management
agreements. Payment of the outstanding fees is dependent on collection by the
PC's of fees from third party medical reimbursement organizations, principally
insurance companies and health management organizations.
In the case of contracts with the MRI facilities, fees were charged by the
Company during fiscal 2007 based on the number of procedures performed. In the
case of the physical therapy and rehabilitation practices the Company's
previously managed, flat fees were charged on a monthly basis. Fees are subject
to adjustment on an annual basis, but must be based on mutual agreement. The per
procedure charges to the MRI facilities during fiscal 2007 ranged from $275 to
$500 per MRI scan. Commencing in fiscal 2008, however, eight of the MRI
facilities will be charged a flat fee, pursuant to the new contracts entered
into by the Company following the sale of said MRI facilities at the end of
fiscal 2007 by Dr. Raymond Damadian to an unrelated third party.
As of June 22, 2007, an unrelated third party purchased the stock of the
professional corporations owning the eight New York sites managed by the
Company, previously owned by Dr. Raymond V. Damadian, the President, Chairman of
the Board and principal stockholder of Fonar. In connection with the sale, new
management agreements were substituted for the existing management agreements,
providing, however, for the same management services. The fees in fiscal 2008,
however, will be flat monthly fees in the aggregate amount of $732,250 per
month.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
(Continued)
Accounts Receivable and Management Fee Receivable (Continued)
Dr. Damadian still owns the four MRI facilities in Georgia and Florida managed
by the Company. No MRI facilities or other medical facilities are owned by the
Company.
Collection by the Company of its management fee receivable may be impaired by
the uncollectibility of the PC's medical fees from third party payors,
particularly insurance carriers covering automobile no-fault and workers
compensation claims due to longer payment cycles and rigorous informational
requirements and certain other disallowed claims. Approximately 40% and 42% of
the PC's net revenues for both the three months ended September 30, 2007 and
2006, respectively, were derived from no-fault and personal injury protection
claims. The Company considers the aging of its accounts receivable in
determining the amount of allowance for doubtful accounts and contractual
allowances. The Company generally takes all legally available steps to collect
its receivables. Credit losses associated with the receivables are provided for
in the condensed consolidated financial statements and have historically been
within management's expectations.
Certain no-fault insurers have raised issues concerning whether the Company's
clients, the "P.C.'s," are in compliance with certain laws, including, but not
limited to, laws governing their corporate structure and/or licensing, their
entitlement or standing to seek and/or obtain no-fault benefits, and/or laws
prohibiting the corporate practice of medicine, fee-splitting and/or physician
self referrals. To the extent any claims are asserted against the P.C.'s, the
Settlement of such claims could result in the P.C.'s waiving their rights to
collect certain of their insurance claims. Management believes that the Company
and the P.C.'s are not in violation of any of the above mentioned laws. Since
the resolution or settlement of these claims with the insurance companies could
have a material impact on the collection of management fees by the Company from
its P.C.'s, the Company has provided reserves for uncollectable fees related to
this matter.
On February 8, 2006, the Deficit Reduction Act of 2005 ("DRA") was signed into
law by President George W. Bush. The DRA would result in caps on Medicare and
Medicaid payment rates for most imaging services, including MRI and CT,
furnished in physicians' offices and other non-hospital based settings. Under
the cap, payments for these imaging services could not exceed the hospital
outpatient payment rates for those services. This change applied to services
furnished by the P.C.'s on or after January 1, 2007. Although the professional
corporations managed by the Company bill for scans on a "global" basis, which
means a single fee per scan, the limitation is applicable only to the technical
component of the services, which is the payment or portion of the payment
attributable to the non-professional services. If the fee for the technical
component of the service (without including geographic adjustments) exceeds the
hospital outpatient payment amount for the service (also without including
geographic adjustments), under the Physician Fee Schedule, then the payment
would be limited to the Physician Fee Schedule rate.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
(Continued)
Accounts Receivable and Management Fee Receivable (Continued)
Currently, a statute in the State of Florida required all drivers, licensed in
the State of Florida, to carry a $10,000 no-fault insurance policy covering
personal injury protection benefits. This statute expired in October 2007 but
will be in effect again in a slightly revised form on January 1, 2008.
Management does not believe that the expiration of this statute will have a
material impact on the Company's condensed consolidated financial position or
results of consolidated operations in the future.
While the Company has prepared certain estimates of the impact of the above
discussed changes and possible changes, it is not possible to fully quantify
their impact on its business. There can be no assurance that the impact of these
changes will not be greater than estimated or that any future health care
legislation or reimbursement changes will not adversely affect the Company's
business.
Net revenues from management and other fees charged to the related P.C.'s
accounted for approximately 17.0% and 36.0% of the consolidated net revenues for
the three months ended September 30, 2007 and 2006, respectively. Product sales
and service repair fees from related parties amounted to approximately 1.1% and
4.9% of consolidated net revenues for the three months ended September 30, 2007
and 2006 respectively.
HMCA entered into a management agreement in September 2007 with Integrity
Healthcare Management Inc ("Integrity"). Under the terms of the agreement,
Integrity will provide the billings and collections for HMCA's facilities as
well as assist in the management of the facilities. The existing management
agreements between the facilities and HMCA will remain in place. Integrity will
receive as compensation an annual fee equal to one-half of the increase in the
consolidated cash flow of HMCA and the facilities over the period from July 1,
2006 through June 30, 2007. The term of the agreement is one year with an
automatic year to year renewal, but may be terminated by either party without
cause at the end of any year. As of September 30, 2007, no management fees were
earned by Integrity. Integrity is a subsidiary of Health Diagnostics, LLC. The
Chief Operating Officer of Health Diagnostics, LLC, Timothy Damadian, is a son
of the President and Chief Executive Officer of Fonar, Dr. Raymond Damadian. In
July 2007, Integrity and related parties sold a business (consisting of
management companies and diagnostic centers) to Health Diagnostics, LLC and
subsequently accepted a three year employment position (non-equity) with Health
Diagnostics, LLC. At the time, Health Diagnostics, LLC purchased the above
business, Fonar sold its entire 20% interest in a Bronx diagnostic business and
its entire 50% interest in a Florida management company to Healthcare
Diagnostic, LLC (see Note 8). From time to time Health Diagnostics, LLC may
purchase MRI systems from Fonar. As of September 30, 2007, Health Diagnostics,
LLC had placed order with Fonar to purchase six Upright(TM) MRI systems.
Unaudited Financial Information of Unconsolidated Managed Medical Practices
Audited financial information related to the unconsolidated related and
unrelated P.C.'s managed by the Company is not available. Substantially all of
these medical practices' books and records are maintained on a cash basis, they
depreciate their equipment on an accelerated tax basis and have a December 31
year end.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE
(Continued)
Summarized income statement data for the three months ended September 30, 2007
and 2006 related to the unconsolidated medical practices managed by the Company
is as follows:
(000's omitted) (Income Tax-Cash Basis)
For the three months ended September 30,
2007 2006
-------- --------
Patient Revenue - Net $ 4,369 $ 4,762
======== ========
(Loss) Income from Operations $ (327) $ 183
======== ========
Net Loss $ (472) $ ( 59)
======== ========
NOTE 4 - INVENTORIES
Inventories included in the accompanying condensed consolidated balance sheet at
September 30, 2007 consist of:
(000's omitted)
Purchased parts, components
and supplies $ 2,936
Work-in-process 1,840
-------
$ 4,776
=======
NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER
ADVANCES
1) Information relating to uncompleted contracts as of September 30, 2007 is
as follows: (000's omitted)
Costs incurred on uncompleted
contracts $ 3,904
Estimated earnings 1,731
--------
5,635
Less: Billings to date 10,510
--------
$(4,875)
========
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER
ADVANCES (Continued)
Included in the accompanying condensed consolidated balance sheet at September
30, 2007 under the following captions:
Costs and estimated earnings in excess of
billings on uncompleted contracts $ 31
Less: billings in excess of costs and estimated
earnings on uncompleted contracts 4,906
--------
$(4,875)
========
2) Customer advances consist of the following as of September 30, 2007:
Related
Total Party Other
-------- -------- -------
Total Advances $ 21,671 $ 492 $ 21,179
Less: Advances
on contracts under construction 10,510 -- 10,510
-------- -------- --------
$ 11,161 $ 492 $ 10,669
======== ======== ========
NOTE 6 -STOCKHOLDERS' EQUITY
Common Stock
During the three months ended September 30, 2007:
a) The Company issued 20,000 shares of common stock for costs and
expenses of $134,739.
NOTE 7 - OTHER CURRENT LIABILITIES
Other current liabilities in the accompanying condensed consolidated balance
sheet consist of the following:
(000's omitted)
September 30, June 30,
2007 2007
------------- -------------
Royalties $ 571 $ 635
Accrued salaries, commissions
and payroll taxes 1,373 1,106
Accrued interest 604 573
Litigation accruals 193 193
Sales tax payable 3,012 3,037
Other 1,647 2,211
------------- -------------
$ 7,400 $ 7,755
============= =============
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 8 - SALE OF INVESTMENT AND CONSOLIDATED SUBSIDIARY
Sale of Investment
------------------
On July 31, 2007, the Company sold its 20% equity interest in an unconsolidated
entity (management company for a diagnostic center) to an unrelated third party
(see note 3). The selling price was $629,195. The Company realized a gain on the
sale of the equity interest of $571,161.
The gain was calculated as follows:
Selling Price: $629,195
Less: Closing costs (58,034)
Selling Price - Net cash paid 571,161
Cost Basis -
---------
Gain on sale of investment $571,161
=========
Sale of Consolidated Subsidiary
-------------------------------
On July 31, 2007, the Company sold its 50% interest (to an unrelated third
party) (see note 3) in an entity that provided management services to a
diagnostic center in Orlando, FL. The Company continues to manage other
diagnostic centers in the Florida region.
The unrelated third party purchased all assets and assumed all liabilities of
the diagnostic center which included cash, the management fee receivable,
furniture and fixtures and other miscellaneous assets. The purchase price for
the 50% interest was $4,499,768 and after closing costs the amount received was
$4,256,372.
The following is the calculation of the gain on sale of the 50% interest in a
consolidated subsidiary:
Selling Price: $4,499,768
Less: Closing costs (243,396)
-----------
Selling Price - Net cash paid: 4,256,372
Assets sold:
Cash $ 114,238
Management fee
receivable 1,166,100
Property and
equipment - net 22,673
Other assets 14,759
Minority interest (456,373)
------------
Subtotal 861,397
-----------
Gain on sale of consolidated subsidiary $3,394,975
===========
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 9 - SEGMENT AND RELATED INFORMATION
The Company operates in two industry segments - manufacturing and the servicing
of medical equipment and management of diagnostic imaging centers.
The accounting policies of the segments are the same as those described in the
summary of significant accounting policies as disclosed in the Company's 10-K as
of June 30, 2007. All inter-segment sales are market-based. The Company
evaluates performance based on income or loss from operations.
Summarized financial information concerning the Company's reportable segments is
shown in the following table:
(000's omitted)
Management
of
Diagnostic
Medical Imaging
Equipment Centers Totals
--------- ---------- ---------
For the three months ended September 30, 2007:
Net revenues from external customers $ 5,308 $ 3,361 $ 8,669
Inter-segment net revenues $ 235 $ - $ 235
(Loss) Income from operations $ (4,185) $ 79 $(4,106)
Depreciation and amortization $ 330 $ 228 $ 558
Capital expenditures $ 275 $ 51 $ 326
Identifiable assets $ 23,453 $18,726 $42,179
For the three months ended September 30, 2006:
Net revenues from external customers $ 4,979 $ 2,804 $ 7,783
Inter-segment net revenues $ 183 $ - $ 183
Loss from operations $ (5,577) $ (514) $ (6,091)
Depreciation and amortization $ 383 $ 273 $ 656
Compensatory element of stock issuances $ 93 $ 5 $ 98
Capital expenditures $ 434 $ 32 $ 466
Identifiable assets - June 30, 2007 $ 21,098 $20,112 $ 41,210
NOTE 10 - SUPPLEMENTAL CASH FLOW INFORMATION
During the three months ended September 30, 2007 and September 30, 2006, the
Company paid $62,000 and $71,000 for interest, respectively.
NOTE 11 - COMMITMENTS AND CONTINGENCIES
Litigation
The Company is subject to legal proceedings and claims arising from the ordinary
course of its business, including personal injury, customer contract and
employment claims. In the opinion of management, the aggregate liability, if
any, with respect to such actions, will not have a material adverse effect on
the consolidated financial position or results of operations of the Company.
FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2007
(UNAUDITED)
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Continued)
Litigation (Continued)
Certain no-fault insurers have raised issues concerning whether the Company's
clients the "P.C.'s" are in compliance with certain laws, including, but not
limited to, laws governing their corporate structure and/or licensing, their
entitlement or standing to seek and/or obtain no-fault benefits, and/or laws
prohibiting the corporate practice of medicine, fee-splitting and/or physician
self referrals. To the extent any claims are asserted against the P.C.'s, the
settlement of such claims could result in the P.C.'s waiving their rights to
collect certain of their insurance claims. Management believes that the Company
and the P.C.'s are not in violation of any of the above mentioned laws. Since
the resolution or settlement of these claims with the insurance companies could
have a material impact on the collection of management fees by the Company from
its P.C.'s, the Company has provided reserves for uncollectable fees related to
this matter.
Other Matters
In March 2007, the Company and New York State taxing authorities conducted a
conference to discuss a sales tax matter to determine if certain sales
transactions are subject to sales tax withholdings. At the present time, such
discussions are ongoing and the Company cannot yet determine the outcome.
Management is of the belief the resolution of this matter will not materially
impact the consolidated financial statements. The Company has recorded a
provision of $250,000 to cover any potential tax liability including interest.
Such amount is the Company's best estimate of the tax liability. Management is
unable to determine the outcome of this uncertainty.
The Company is also delinquent in filing sales tax returns for certain states,
for which the Company has transacted business. As of September 30, 2007, the
Company has recorded tax obligations of approximately $1,620,000 plus interest
and penalties of approximately $1,000,000. The Company is in the process of
determining the regulatory requirements in order to become compliant.
The Company has determined they may not be in compliance with the Department of
Labor and Internal Revenue Service regulations concerning the requirements to
file Form 5500 to report activity of its 401(k) Employee Benefit Plan. The
filings do not require the Company to pay tax, however they may be subject to
penalty for non-compliance. The Company has recorded provisions for any
potential penalties totaling $250,000. Such amount is the Company's best
estimate of potential penalties. Management is unable to determine the outcome
of this uncertainty. The Company has engaged outside counsel to handle such
matters to determine the necessary requirements to ensure compliance. Such
non-compliance could impact the eligibility of the plan.
NOTE 12 - SUBSEQUENT EVENTS
Common Stock
During the period from October 1, 2007 through October 31, 2007:
a) The Company issued 54 shares of common stock to employees as compensation
valued at $317 under stock bonus plans.
FONAR CORPORATION AND SUBSIDIARIES
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
For the three month period ended September 30, 2007, we reported a net loss
of $209,000 on revenues of $8.7 million as compared to net loss of $6.1 million
on revenues of $7.8 million for the three month period ended September 30, 2006.
We note improvement in both our net loss and revenues for the quarter ended
September 30, 2007 as compared to the quarter ended September 30, 2006. Net
losses improved by 96.6%, ($209,000 as compared to $6.1 million), on a revenue
increase of 11.4% ($8.7 million as compared to $7.8 million).
Operating losses improved by 32.6% ($4.1 million for the first three months
of fiscal 2008 as compared to $6.1 million for the first three months of fiscal
2007). The larger portion of the improvement in the net loss was due to gains
realized on the sale in July 2007 of our 50% interest in a consolidated entity
and our 20% interest in unconsolidated entity to an unrelated third party. We
received proceeds of approximately $4.8 million and recognized gains of
approximately $4.0 million in the aggregate. Both entities were engaged in the
business of managing MRI facilities.
We believe the improvements in our operating results have resulted in part
from reduced apprehension on the part of Fonar Upright(TM) MRI customers
regarding the anticipated negative impact of the Deficit Reduction Act (DRA) on
scanner income and the magnitude of the impact. We believe direct experience by
Fonar Upright(TM) MRI customers with the DRA's revenue impact since it became
effective January 1, 2007 has been largely offset by the growth in demand for
Upright(TM) MRI scans because of the unique benefits of the Fonar Upright(TM)
MRI. This has encouraged them in their plans and encouraged other physicians to
proceed with their plans to purchase Fonar Upright(TM) MRI scanners.
In addition, we have reduced our total costs and expenses by 7.9%, from
$13.9 million in the first quarter of fiscal 2007 to $12.8 million in the first
quarter of fiscal 2008. This was primarily the result of our improved and
streamlined advertising program, which enabled us to reduce advertising and
trade show expenditures by approximately $772,000. Overall, there was a
reduction of our selling, general and administrative costs of 17.7%, from $6.4
million in the first quarter of fiscal 2007 to $5.3 million in the first quarter
of fiscal 2008.
In addition, we plan to continue to expand our sales force, both in terms
of hiring more sales personnel and establishing a network of domestic
distributors, as well as improving our network of foreign distributors.
We also are monitoring the performance of our existing users in order to
establish teams to assist underperforming customers improve their scan volume.
In addition, we have held seminars to assist customers in their marketing
efforts and are in the process of developing a web site to assist our customers
in their marketing efforts.
Importantly, we are beginning to penetrate the hospital market. The Fonar
Upright(TM) MRI scanner is the only scanner which enables weight-bearing scans
of the spine, which is critical in making a correct diagnosis of spine diseases
such as low back pain and therefore the key to performing the correct surgery of
the spine.
Forward Looking Statements
Certain statements made in this Quarterly Report on Form 10-Q are
"forward-looking statements" (within the meaning of the Private Securities
Litigation Reform Act of 1995) regarding the plans and objectives of Management
for future operations. Such statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements. The
forward-looking statements included herein are based on current expectations
that involve numerous risks and uncertainties. Our plans and objectives are
based, in part, on assumptions involving the expansion of business. Assumptions
relating to the foregoing involve judgments with respect to, among other things,
future economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict accurately and
many of which are beyond our control. Although we believe that our assumptions
underlying the forward-looking statements are reasonable, any of the assumptions
could prove inaccurate and, therefore, there can be no assurance that the
forward-looking statements included in this Report will prove to be accurate. In
light of the significant uncertainties inherent in the forward-looking statement
included herein, the inclusion of such information should not be regarded as a
representation by us or any other person that our objectives and plans will be
achieved.
Results of Operations
We operate in two industry segments: the manufacture and servicing of
medical (MRI) equipment, our traditional business which is conducted directly by
Fonar, and diagnostic facilities management services, which is conducted through
Fonar's wholly-owned subsidiary, Health Management Corporation of America, which
we also refer to as HMCA. During July 2007 HMCA sold its 50% interest in a
consolidated entity for approximately $4.3 million and its 20% interest in an
unconsolidated entity for approximately $571,000 to an unrelated third party.
Trends in the first quarter of fiscal 2008 include an increase in product
sales revenues, service and repair fees, and management and other fees, and a
decrease in total costs and expenses. We will continue to focus on increased
marketing efforts, including advertising, and adding additional sales personnel
and distributors, where appropriate, to improve sales performance in fiscal
2008. During fiscal 2007, the Company also hired an additional advertising and
marketing executive, who had previously been associated with our independent
advertising agency. In addition, we will continue our efforts to reduce costs
through our procurement policies and streamlining our operations.
For the three month period ended September 30, 2007, as compared to the
three month period ended September 30, 2006, overall revenues from MRI product
sales increased 5.4% ($2.6 million compared to $2.5 million). Unrelated party
scanner sales ($2.6 million compared to $2.3 million) increased at a rate of
11.7%. There were no related party scanner sales for the three month period
ended September 30, 2007 compared to $139,000 for the three month period ended
September 30, 2006.
Service revenues, increased by 7.8% ($2.7 million compared to $2.5 million)
because of additional customers entering into service agreements with Fonar for
their scanners following the expiration of the warranty period on their
equipment. Unrelated party service and repair fees increased by 8.1% ($2.4
million compared to $2.3 million) and related party service and repair fees
increased by 5.0% ($254,000 compared to $242,000). We anticipate that there will
continue to be increases in service revenues as warranties on installed scanners
expire over time.
There were approximately $198,000 in foreign revenues for the first three
months of fiscal 2008 as compared to approximately $259,000 in foreign revenues
for the first three months of fiscal 2007, representing a decrease in foreign
revenues of 23.6%. The Company is making a concerted effort to increase foreign
sales, most recently through its foreign distributors and attendance at trade
shows.
Overall, for the first quarter of fiscal 2008, revenues for the medical
equipment segment increased by 6.6% to $5.3 million from $5.0 million for the
first quarter of fiscal 2007. The revenues generated by HMCA increased, by 19.9%
to $3.4 million for the first quarter of fiscal 2008 as compared to $2.8 million
for the first quarter of fiscal 2007.
We recognize MRI scanner sales revenues on the "percentage of completion"
basis, which means the revenues are recognized as the scanner is manufactured.
Revenues recognized in a particular quarter do not necessarily reflect new
orders or progress payments made by customers in that quarter. We build the
scanner as the customer meets certain benchmarks in its site preparation in
order to minimize the time lag between incurring costs of manufacturing and our
receipt of the cash progress payments from the customer which are due upon
delivery. Consequently, there can be a disparity between the revenues recognized
in a fiscal period and the number of product sales. Generally, the recognized
revenue results from revenues from a scanner sale are recognized in a fiscal
quarter or quarters following the quarter in which the sale was made.
Costs related to product sales increased by 8.7% from $2.6 million in the
first quarter of fiscal 2007 to $2.8 million in the first quarter of 2008,
reflecting the corresponding increase in product sales revenues. Costs related
to providing service decreased by 4.5% from $1.4 million in the first quarter of
fiscal 2007 to $1.3 million in the first quarter of 2008, notwithstanding the
increase in service and repair revenues.
Service and repair revenues increased at a materially higher rate than the
costs related to providing service and repairs. Service contract prices are
fixed for the term of the contract, which are usually for a term of one year. We
believe that an important factor in keeping service costs down is our ability to
monitor the performance of customers' scanners from our facilities in Melville
on a daily basis and to detect and repair any irregularities before more serious
problems result. We also believe the low cost of providing service reflects the
high quality of our products.
Overall, our operating loss for our medical equipment segment was $4.2
million for the first three months of fiscal 2008 as compared to operating loss
of $5.6 million for the first three months of fiscal 2007.
HMCA revenues increased in the first quarter of fiscal 2008, by 19.9% to
$3.4 million from $2.8 million for the first quarter of fiscal 2007 due to fee
structure change to the eight New York facilities we manage. We now manage ten
sites equipped with Upright(TM) MRI scanners. HMCA experienced an operating
income of $79,000 for the first three months of fiscal 2008 compared to
operating loss of $514,000 for the first three months of fiscal 2007.
HMCA cost of revenues for the first quarter of fiscal 2008 remained
constant at $2.0 million for the first quarter of fiscal 2008 and 2007.
As of June 22, 2007, Dr. Robert Diamond purchased the stock of the
professional corporations owning the eight New York sites managed by HMCA,
previously owned by Dr. Raymond V. Damadian, the President, Chairman of the
Board and principal stockholder of Fonar. In connection with the sale, new
management agreements were substituted for the existing management agreements,
providing, however, for the same management services. The fees in fiscal 2008,
however, will be flat monthly fees in the aggregate amount of $732,250 per
month.
For the purpose of improving the performance of HMCA and the facilities,
HMCA entered into an agreement in September, 2007 with Integrity Healthcare
Management, Inc. ("Integrity"), which is a wholly-owned subsidiary of Health
Diagnostics, LLC. The Chief Operating Officer of Health Diagnostics, LLC,
Timothy Damadian is a son of the President and Chief Executive Officer of Fonar,
Dr. Raymond Damadian. Under the terms of the agreement, Integrity will supervise
and direct HMCA and the management of the facilities. The existing management
agreements between the facilities and HMCA will remain in place. Integrity will
receive as compensation an annual fee equal to one-half of the increase in the
consolidated cash flow of HMCA and the facilities over the period from July 1,
2006 through June 30, 2007. The term of the agreement is on an automatically
renewable year to year basis, but may be terminated by either party without
cause at the end of any year. From time to time Health Diagnostics, LLC, may
also purchase MRI scanners from Fonar. As of September 30, 2007, Healthcare
Diagnostics, LLC had placed orders with Fonar to purchase six Upright(TM) MRI
scanners.
On February 8, 2006, the Deficit Reduction Act of 2005 ("DRA") was signed
into law by President George W. Bush. The DRA, which went into effect in the
beginning of calendar 2007, places caps on Medicare and Medicaid payment rates
for most imaging services, including MRI and CT, furnished in physicians'
offices and other non-hospital based settings. Under the cap, payments for these
imaging services cannot exceed the hospital outpatient payment rates for those
services. This change applies to services furnished by the professional
corporations managed by HMCA on or after January 1, 2007. Although the
professional corporations managed by HCMA bill for scans on a "global" basis,
which means a single fee per scan, the limitation is applicable only to the
technical component of the services, which is the payment or portion of the
payment attributable to the non-professional services. If the fee for the
technical component of the service (without including geographic adjustments)
exceeds the hospital outpatient payment amount for the service (also without
including geographic adjustments), under the Physician Fee Schedule, then the
payment would be limited to the Physician Fee Schedule rate.
Currently, a statute in the State of Florida requires all drivers licensed
in the State of Florida to carry a $10,000 no-fault insurance policy covering
personal injury protection benefits. This statute expired in October 2007.
Management does not believe that the expiration of this statute will have a
material impact on our consolidated financial position or results of
consolidated operations.
While we have prepared certain estimates of the impact of the above
discussed changes and possible changes, it is not possible to fully quantify
their impact on our business. There can be no assurance that the impact of these
changes will not be greater than estimated or that any future health care
legislation or reimbursement changes will not adversely affect our business.
The increase in our total net revenues of 11.4% from $7.8 million in the
first three months of fiscal 2007 to $8.7 million in the first three months of
fiscal 2008, was accompanied by a decrease of 7.9% in total costs and expenses
from $13.9 million in the first three months of fiscal 2007 compared to $12.8
million in the first three months of fiscal 2008. As a result, our operating
loss decreased from $6.1 million in the first three months of fiscal 2007 to
$4.1 million in the first three months of fiscal 2008.
Selling, general and administrative expenses decreased by 17.7% from $5.3
million in the first three months of fiscal 2008 from $6.4 million in the first
three months of fiscal 2007. The compensatory element of stock issuances, which
is now included in selling, general and administrative expenses, decreased from
$98,000 in the first three months of fiscal 2007 to $0 in the first three months
of fiscal 2008. This reflects a lesser use of Fonar's stock in lieu of cash to
pay employees, consultants and professionals for services.
Research and development expenses decreased by 18.8 % to $1.2 million for
the first three months of fiscal 2008 as compared to $1.4 million for the first
three months of fiscal 2007.
Interest expense in the first three months of fiscal 2008 increased by
43.7% to $102,000 from $71,000 for the first three months of fiscal 2007.
Inventories increased by 6.9% to $4.8 million at September 30, 2007 as
compared to $4.5 million at June 30, 2007 as the Company's, representing our
purchase of raw materials and components to fill orders.
Management fee and medical receivables decreased by 6.5% to $8.6 million at
September 30, 2007 from $9.2 million at June 30, 2007, primarily due to
collections on the Company's medical receivables.
The overall trends reflected in the results of operations for the first
three months of fiscal 2008 are an increase in revenues from product sales, as
compared to the first three months of fiscal 2007 ($2.6 million for the first
three months of fiscal 2008 as compared to $2.5 million for the first three
months of fiscal 2007), and a decrease in MRI equipment segment revenues
relative to HMCA revenues ($5.3 million or 61% from the MRI equipment segment as
compared to $3.4 million or 39% from HMCA, for the first three months of fiscal
2008, as compared to $5.0 million or 64% from the MRI equipment segment and $2.8
million or 36%, from HMCA, for the first three months of fiscal 2007). In
addition, we experienced an increase in unrelated party sales relative to
related party sales in our medical equipment product sales ($2.6 million or 100%
to unrelated parties for the first three months of fiscal 2008 as compared to
$2.3 million, or 94% to unrelated parties and $139,000 or 6% to related parties
for the first three months of fiscal 2007).
We are committed to continuing the improvement in our operating results we
experienced in the first three months in fiscal 2008. Nevertheless, factors
beyond our control, such as the timing and rate of market growth which depend on
economic conditions, payor reimbursement rates and policies, and unexpected
expenditures or the timing of such expenditures, make it impossible to forecast
future operating results. We believe we are pursuing the correct policies which
should prove successful in improving the Company's operating results.
Our Upright(TM) MRI, and Fonar-360(TM) MRI scanners, together with our
works-in-progress, are intended to significantly improve our competitive
position.
Our Upright(TM) MRI scanner, which operates at 6000 gauss (.6 Tesla) field
strength, allows patients to be scanned while standing, sitting, reclining and
in multiple flexion and extension positions. It is common in visualizing the
spine that abnormalities are visualized in some positions and not others. This
enables surgical corrections that heretofore would be unaddressable for lack of
visualizing the symptom causing the pathology. A floor-recessed elevator brings
the patient to the height appropriate for the targeted image region. A
custom-built adjustable bed will allow patients to sit or lie on their backs,
sides or stomachs at any angle. Full-range-of-motion studies of the joints in
virtually any direction are possible and another promising feature for sports
injuries. Most recently a new important application has been discovered for the
Fonar Upright(TM) MRI, namely the evaluation of spinal scoliosis in young women.
In a 2000 publication of the National Cancer Institute women with scoliosis were
discovered to have a 70% increase in breast cancer which was presumed to arise
from the repeated chest x-rays needed to monitor treatment. Upright(TM) MRI is
now available to provide a radiation-free alternative to meet this need.
The Upright MRI(TM) will also be useful for MRI directed neuro-surgical
procedures as the surgeon would have unhindered access to the patient's head
when the patient is supine with no restrictions in the vertical direction. This
easy-entry, mid-field-strength scanner should be ideal for trauma centers where
a quick MRI-screening within the first critical hour of treatment will greatly
improve patients' chances for survival and optimize the extent of recovery.
The Fonar 360(TM) is an enlarged room sized magnet in which the floor,
ceiling and walls of the scan room are part of the magnet frame. This is made
possible by Fonar's patented Iron-Frame(TM) technology which allows the
Company's engineers to control, contour and direct the magnet's lines of flux in
the patient gap where wanted and almost none outside of the steel of the magnet
where not wanted. Consequently, this scanner allows surgeons and other
interventional physicians to walk inside the magnet and achieve 360 degree
access to the patient to perform interventional procedures.
The Fonar 360(TM) is presently marketed as a diagnostic scanner and is
sometimes referred to as the Open Sky(TM) MRI. In its Open Sky(TM) version, the
Fonar 360(TM) serves as an open patient friendly scanner which allows 360 degree
access to the patient on the scanner bed. To optimize the patient-friendly
character of the Open Sky(TM) MRI, the walls, floor, ceiling and magnet poles
are decorated with landscape murals. The patient gap is twenty inches and the
magnetic field strength, like that of FONAR's Upright MRI(TM), is 0.6 Tesla.
In the future, we expect the Fonar 360(TM) to function as an interventional
MRI. The enlarged room sized magnet and 360 access to the patient afforded by
the Fonar 360(TM) would permit surgeons to walk into the magnet and perform
interventions on the patient inside the magnet. Most importantly the exceptional
quality of the MRI image and its capacity to exhibit tissue detail on the image,
can then be obtained real time during the procedure to guide the
interventionalist. Thus surgical instruments, needles, catheters, endoscopes and
the like could be introduced directly into the human body and guided to the
malignant lesion by means of the MRI image. The number of inoperable lesions
should be greatly reduced by the availability of this new capability. Most
importantly treatment can be carried directly to the target tissue. The
interventional features of the Fonar 360(TM) are expected to be implemented by
Oxford Nuffield Orthopedic Center in Oxford U.K. in the near future. A full
range of MRI compatible surgical instruments using ceramic cutting tools and
beryllium-copper materials are available commercially.
The Company expects marked demand for its most commanding MRI products, the
Upright MRI(TM) and the Fonar 360(TM), first for their exceptional features in
patient diagnosis and treatment. These scanners additionally provide improved
image quality and higher imaging speed because of their higher field strength of
..6 Tesla. The geometry of the Upright MRI(TM) as compared to a single coil, or
multiple coils on only one axis and its transverse magnetic field enables the
use of two detector rf coils operating in quadrature which increases the Upright
MRI(TM) signal to noise ratio by 40%, providing a signal to noise ratio equal to
a .84T recumbent only MRI scanner.
Liquidity and Capital Resources
Cash, cash equivalents and marketable securities increased from $3.4
million at June 30, 2007 to $4.2 million at September 30, 2007. Principal uses
of cash during the first three months of fiscal 2008 included capital
expenditures for property and equipment of $51,000, repayment of long-term debt
and capital lease obligations in the amount of $56,000, capitalized software
development costs of $187,000 and capitalized patent costs of $88,000, and a
decrease in accounts payable of $625,000, which was offset by proceeds from the
sale of our interest in consolidated subsidiary of $4.1 million and proceeds
from sales of an investment of $571,000.
Marketable securities approximated $2.7 million as at September 30, 2007,
as compared to $2.0 million at June 30, 2007. This increase represents the
investment of a portion of the proceeds from the sale of our interest in a
consolidated subsidiary and investment. At September 30, 2007, our investments
in U.S. Government obligations were $498,000, our investments in corporate and
government agency bonds were $1.4 million and our investments in certificates of
deposit and deposit notes were $762,000. These investments have had the intended
effect of maintaining a stable investment portfolio.
Cash used in operating activities for the first three months of fiscal 2008
was $3.5 million. Cash used in operating activities was attributable primarily
to the net loss of $209,000, a gain on sale of a consolidated entity of $3.4
million, a gain on sales of an investment of $571,000, an increase in accounts,
management fee and medical receivables of $1.4 million and the decrease in
accounts payable of $625,000, offset by an increase in customer advances of $1.1
million and an increase in billing in excess of costs and estimated earnings on
uncompleted contracts of $1.4 million.
Cash provided by investing activities for the first three months of fiscal
2008 was $3.7 million. The principal source of cash from investing activities
during the first three months of fiscal 2008 consisted of proceeds from the sale
of an investment and consolidated subsidiary of $4.7 million, offset by
expenditures for property and equipment of $51,000 and capitalized software and
patent costs of $275,000.
Cash used in financing activities for the first three months of fiscal 2008
was $149,000. The principal uses of cash in financing activities during the
first three months of fiscal 2008 consisted of repayment of principal on
long-term debt and capital lease obligations of $56,000 and distributions to
holders of minority interests of $95,000.
The Company's contractual obligations and the periods in which they are
scheduled to become due are set forth in the following table:
(000's OMITTED)
Due in
less Due Due Due
Contractual Than 1 in 2-3 in 4-5 after 5
Obligation Total year years years years
-------------- ---------- ---------- ---------- ---------- ----------
Long-term debt $ 543 $ - $ - $ - $ 543
Capital lease
obligation 614 256 336 22 -
Operating
leases 7,055 2,330 2,407 1,324 994
---------- ---------- ---------- ---------- ----------
Total cash
obligations $ 8,212 $ 2,586 $ 2,743 $ 1,346 $ 1,537
========== ========== ========== ========== ==========
Total liabilities increased by 4.5% to $33.1 million at September 30, 2007
from $31.8 million at June 30, 2007.
We experienced a decrease in long-term debt and capital leases from
$956,000 at June 30, 2007 to $901,000 at September 30, 2007 and a decrease in
accounts payable from $3.9 million at June 30, 2007 to $3.3 million at September
30, 2007, offset by an increase in billings in excess of costs and estimated
earnings on uncompleted contracts from $3.4 million at June 30, 2007 to $4.9
million at September 30, 2007, and an increase in customer advances from $10.1
million at June 30, 2007 to $11.1 at September 30, 2007. Unearned revenue on
service contracts remained constant at $5.1 million at June 30, 2007 and
September 30, 2007,
As of September 30, 2007, the total of $7.4 million in other current
liabilities included primarily accrued salaries and payroll taxes of $1.4
million, accrued royalties of $571,000 and excise and sales taxes of $3.0
million.
Our working capital deficit was $7.7 million as of September 30, 2007, as
compared to our working capital deficit of $7.6 million as of June 30, 2007,
increasing by 1.1%. This resulted from an increase in current liabilities ($30.1
million at June 30, 2007 as compared to $32.0 million at September 30, 2007,
particularly an increase in customer advances of $1.0 million ($10.1 million at
June 30, 2007 as compared to $11.2 million at September 30, 2007),
notwithstanding an increase in current assets ($23.0 million at June 30, 2007
compared to $24.4 million at September 30, 2007), including an increase in cash
and cash equivalents and marketable securities of $739,000 ($3.4 million at June
30, 2007 as compared to $4.2 million at September 30, 2007), an increase of cost
and estimated earnings in excess of billings on uncompleted contracts of $31,000
($0 million at June 30, 2007 as compared to $31,000 at September 30, 2007) along
with an increase in inventories of approximately $310,000 ($4.5 million at June
30, 2007 as compared to $4.8 million at September 30, 2007).
With respect to current liabilities, the current portion of long-term debt
decreased from $257,000 at June 30, 2007 to $256,000 at September 30, 2007, and
billings in excess of costs and estimated earnings on uncompleted contracts
increased from $3.5 million at June 30, 2007 to $4.9 million at September 30,
2007. Customer advances increased from $10.1 million at June 30, 2007 to $11.1
million at September 30, 2007 and accounts payable decreased from $3.9 million
at June 30, 2007 to $3.3 million at September 30, 2007. The increase in cash
advances reflects increased customer deposits, and the reduction in accounts
receivable reflects an increased tendency to pay in advance or at the time of
delivery.
Inventories increased by approximately $310,000 ($4.5 million at June 30,
2007 as compared to $4.8 million at September 30, 2007) resulting from an
increase in the purchasing of raw materials and components in order to fill our
backlog of orders.
Fonar has not committed to making additional capital expenditures in the
2008 fiscal year other than to continue research and development expenditures at
current levels.
Our business plan calls for a continuing emphasis on providing our
customers with enhanced equipment service and maintenance capabilities and
delivering state-of-the-art, innovative and high quality equipment upgrades at
competitive prices.
Our principal source of liquidity has been cash flows provided by
operations. We currently expect this to continue. Also, in July 2007, the
Company sold its 50% interest in a consolidated subsidiary and 20% interest in
an unconsolidated entity to an unrelated third party and received proceeds of
approximately $4.8 million. At September 30, 2007, we had working capital
deficit of $7.7 million. For the three months ended September 30, 2007, we
incurred a net loss of $209,000 which included non-cash charges of $858,000.
The Company is focusing on increased advertising and marketing campaigns
and distribution programs to increase the demand for Fonar's products.
Management anticipates that Fonar's capital resources will improve as Fonar's
MRI scanner products gain wider market recognition and acceptance resulting in
increased product sales. If we are not successful with our current marketing
efforts to increase sales, then we could experience a shortfall in the cash
necessary to sustain operations at their current levels.
Given our September 30, 2007 cash and marketable securities balance of $4.2
million, as compared to $3.4 million at June 30, 2007 and our expected cash
requirements, we anticipate that our existing capital resources, funds generated
from operations and funds expected to be received from note repayments, will be
sufficient to satisfy our cash flow requirements through at least September 30,
2008. The increase in cash and marketable securities resulted from the
investment of a portion of the proceeds from the sale of our 50% interest in a
consolidated entity and our 20% interest in an unconsolidated entity. As a
result, marketable securities increased 36.1% from $2.0 million at June 30, 2007
to $2.7 million at September 30, 2007. Based upon current results of operations,
we believe we will either need to increase sales, reduce expenses or seek other
sources of funds through the issuance of equity or debt financing in order to
maintain sufficient funds available to operate subsequent to September 30, 2008.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our investments are in fixed rate instruments. Below is a tabular
presentation of the maturity profile of the fixed rate instruments held by us at
September 30, 2007.
INTEREST RATE SENSITIVITY
PRINCIPAL AMOUNT BY EXPECTED MATURITY
WEIGHTED AVERAGE INTEREST RATE
Investments
Year of in Fixed Rate Weighted Average
Maturity Instruments Interest Rate
-------- ------------- ----------------
9/30/08 $ 661,691 0.00%
9/30/09 999,250 3.76%
9/30/10 998,812 2.61%
9/30/11 - -
9/30/12 - -
-------------
Total: $ 2,659,753
=============
Fair Value
at 9/30/07 $ 2,558,514
=============
All of our revenue, expense and capital purchasing activities are
transacted in United States dollars.
See Note 13 to the consolidated Financial Statements in our Form 10-K as of
and for the year ended June 30, 2007 for information on long-term debt.
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures.
The Company maintains controls and procedures designed to ensure that
information required to be disclosed in the reports that it files or submits
under the Securities Exchange Act of 1934 is recorded, processed, summarized and
reported within the time periods specified in the rules and forms of the
Securities and Exchange Commission. Based upon their evaluation of those
controls and procedures performed as of the end of the period covered by this
report, the principal executive and acting principal financial officer of the
Company concluded that disclosure controls and procedures were effective.
(b) Change in internal controls.
The Company continues to enhance its controls and procedures related to the
financial reporting process, improvements that were established during the
latter part of fiscal 2005. This included hiring an outside consultant to assist
with technical accounting and reporting issues, developing more standardized
closing procedures and implementing a more formal process for documenting the
weekly management meetings to review operating performance and results.
There have been no changes in our internal control over financial reporting
that occurred during the most recent fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings: There were no material changes in litigation for
the first three months of fiscal 2008.
Item 1A - Risk Factors: There were no material changes in risk factors in
the first three months of fiscal 2008 from those
disclosed in our most recent Form 10-K.
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds: None
Item 3 - Defaults Upon Senior Securities: None
Item 4 - Submission of Matters to a Vote of Security Holders: None
Item 5 - Other Information: None
Item 6 - Exhibits and Reports on Form 8-K: Exhibit 31.1 Certification See
Exhibits Exhibit 32.1 Certification See Exhibits 8-K (earnings press
release) filed on October 1, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
FONAR CORPORATION
(Registrant)
By: /s/ Raymond V. Damadian
Raymond V. Damadian
President & Chairman
Dated: November 14, 2007